logo-loader
viewPharmaxis Ltd

Pharmaxis hopeful of FDA approval for cystic fibrosis inhalation medicine Bronchitol by Q1 2020

Pharmaxis confident of FDA approval for cystic fibrosis inhalation medicine Bronchitol by Q1 2020

Pharmaxis Ltd (ASX:PXS) chief executive officer Gary Phillips updates Proactive Investors on the FDA approval timeframe for the company’s Bronchitol inhalation medicine used to treat adult cystic fibrosis patients.

The healthcare-focused company is confident it will meet information requirements for a Q1 2020 approval.

Earlier this year, the FDA Pulmonary and Allergy Drug Advisory Committee (PADAC) released a positive vote that provides a clear path to meet this approval, subject to some further information being provided, which is now being undertaken and delivered.

The CEO also updated the market on the company’s deal with Boehringer for liver disease medicine, as well as its LOXL2 inhibitor program.

Quick facts: Pharmaxis Ltd

Price: 0.077 AUD

ASX:PXS
Market: ASX
Market Cap: $30.43 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) CEO Gary Phillips speaks to Proactive's Andrew Scott after it was announced its US licensee Chiesi Farmaceutici SpA filed a resubmission to the FDA for Bronchitol® . The move addresses issues raised by the US Food and Drug Administration (FDA)...

on 6/5/20

2 min read